IRVINE, Calif.--(BUSINESS WIRE)--Aug. 29, 2016--
Masimo (NASDAQ:
MASI) announced today that in response to the Zika virus and its
potential impact on the availability of blood products, Masimo is
creating a special program to dramatically reduce the cost of and
increase access to Masimo’s continuous hemoglobin monitoring (SpHb®)
solutions, shown to help clinicians reduce blood transfusions in both
low and high blood loss surgery. This special program will be available
wherever the blood supply is affected by the Zika virus.
Masimo’s special program will allow clinicians and institutions in areas
affected by the Zika virus to obtain a 50% discount off the list price
of non-invasive SpHb sensors, and in addition, will make a limited
number of loaner SpHb monitoring devices available at no cost during
this special program.
Joe Kiani, Founder and CEO of Masimo, stated, “Because of how the Zika
virus is transmitted, the FDA has recently recommended that the existing
blood supply be tested for the virus, in addition to adding Zika
screening for new blood donations. While this additional testing is
necessary, it may constrain supplies of usable blood products while also
increasing the cost of blood for a period of time. Masimo wants to do
its part to help clinicians and healthcare facilities mitigate these
issues by dramatically reducing the price of and increasing access to
our SpHb monitoring solutions, which permit continuous, real-time
visibility to changes in hemoglobin levels to help clinicians facilitate
more informed and timely transfusion decisions. Independent, published
studies completed by different researchers on three continents (US1,
Egypt2, Japan3) have shown that SpHb may help
clinicians reduce blood transfusions during different types of surgery*.”
“We believe the use of continuous SpHb monitoring can help reduce demand
for donated blood and the risk posed by blood donated before the
additional testing, which may be infected,” Mr. Kiani added. “In
addition, Masimo will expand its ongoing efforts to increase awareness
of the transfusion reduction benefits of the multidisciplinary pillars
of Patient Blood Management, including the importance of pre-operative
screening and therapies to safely increase patients’ hemoglobin levels
before elective surgery4.”
@MasimoInnovates |
#Masimo
*Clinical decisions regarding red blood cell transfusions should be
based on the clinician’s judgment considering, among other factors:
patient condition, continuous SpHb monitoring, and laboratory diagnostic
tests using blood samples.
References
-
Ehrenfeld JM et al. J Blood Disorders Transf. 2014. 5:9. 2.
-
Awada WN et al. J Clin Monit Comput. 2015 Feb 4.
-
Imaizumi et al. Continuous and noninvasive hemoglobin monitoring may
reduce excessive intraoperative RBC transfusion. Proceedings from the
16th World Congress of Anaesthesiologists, Hong Kong. Abstract #PR607.
-
Meybohm P et al. Patient Blood Management is Associated With a
Substantial Reduction of Red Blood Cell Utilization and Safe for
Patient’s Outcome. Ann Surg. 2016;264:203-211.
About Masimo
Masimo (NASDAQ: MASI) is a global leader in innovative noninvasive
monitoring technologies. Our mission is to improve patient outcomes and
reduce the cost of care by taking noninvasive monitoring to new sites
and applications. In 1995, the company debuted Masimo SET®
Measure-through Motion and Low Perfusion™ pulse oximetry, which has been
shown in multiple studies to significantly reduce false alarms and
accurately monitor for true alarms. Masimo SET® is estimated
to be used on more than 100 million patients in leading hospitals and
other healthcare settings around the world. In 2005, Masimo introduced
rainbow® Pulse CO-Oximetry technology, allowing noninvasive
and continuous monitoring of blood constituents that previously could
only be measured invasively, including total hemoglobin (SpHb®),
oxygen content (SpOC™), carboxyhemoglobin (SpCO®),
methemoglobin (SpMet®), and more recently, Pleth Variability
Index (PVI®) and Oxygen Reserve Index (ORI™), in addition to
SpO2, pulse rate, and perfusion index (PI). In 2014, Masimo
introduced Root®, an intuitive patient monitoring and
connectivity platform with the Masimo Open Connect™ (MOC-9™) interface.
Masimo is also taking an active leadership role in mHealth with products
such as the Radius-7™ wearable patient monitor and the MightySat™
fingertip pulse oximeter. Additional information about Masimo and its
products may be found at www.masimo.com.
All published clinical studies on Masimo products can be found at http://www.masimo.com/cpub/clinical-evidence.htm.
Forward-Looking Statements
This press release includes forward-looking statements as defined in
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, in connection with the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements include, among others, statements regarding the potential
effectiveness of Masimo SpHb®. These forward-looking
statements are based on current expectations about future events
affecting us and are subject to risks and uncertainties, all of which
are difficult to predict and many of which are beyond our control and
could cause our actual results to differ materially and adversely from
those expressed in our forward-looking statements as a result of various
risk factors, including, but not limited to: risks related to our
assumptions regarding the repeatability of clinical results; risks
related to our belief that Masimo's unique noninvasive measurement
technologies, including Masimo SpHb, contribute to positive clinical
outcomes and patient safety; risks related to our belief that Masimo
noninvasive medical breakthroughs provide cost-effective solutions with
comparable accuracy and unique advantages, including: immediate and
continuous results that enable earlier treatment without causing
invasive trauma in all patients and in every clinical situation; as well
as other factors discussed in the "Risk Factors" section of our most
recent reports filed with the Securities and Exchange Commission
("SEC"), which may be obtained for free at the SEC's website at www.sec.gov.
Although we believe that the expectations reflected in our
forward-looking statements are reasonable, we do not know whether our
expectations will prove correct. All forward-looking statements included
in this press release are expressly qualified in their entirety by the
foregoing cautionary statements. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of
today's date. We do not undertake any obligation to update, amend or
clarify these statements or the "Risk Factors" contained in our most
recent reports filed with the SEC, whether as a result of new
information, future events or otherwise, except as may be required under
the applicable securities laws.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160829005437/en/
Source: Masimo
Masimo
Evan Lamb, 949-396-3376
elamb@masimo.com